Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19
Date:1/19/2011

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Santarus, Inc. (Nasdaq: SNTS) announces that a live audio webcast and accompanying slide presentation will be provided for its Analyst Day and Investor Briefing.  

Details of the event are as follows:What:Santarus Analyst Day and Investor BriefingWhen:Today, Wednesday, January 19, 2011 at 4:15 p.m. Eastern timeWhere:www.santarus.com (under the Investor Relations link)AGENDA

  • Strategic Overview and 2011 Financial Outlook


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

  • CYCLOSET® - Clinical/Medical Background


  • Dr. J. Michael Gaziano, Chief, Division of Aging, Brigham & Women’s Hospital,


    Professor of Medicine, Harvard Medical School

  • ULTESA™ (Budesonide MMX®) – Overview and Top-line Phase III Clinical Study Results


  • Dr. Simon P.L. Travis, Consultant Gastroenterologist,


    Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

  • Ulcerative Colitis – Treatment Perspective


  • Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology,


    University of California, San Diego

  • RHUCIN® and Hereditary Angioedema (HAE)


  • Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Allergy and Immunology, University of California, San Diego,


    Research Scientist, San Diego VA Healthcare

  • SAN-300 (anti-VLA-1 antibody)


  • Dr. Mark C. Totoritis, Senior Vice President, Biologics, Santarus, Inc.

  • Wrap-up/Question & Answer Session


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

    How:Live over the Internet – Simply log on to the Investor Relations section of the company's website at www.santarus.comContact:Lippert/Heilshorn & AssociatesNarine Darbinyan310-691-7100About SantarusSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.  The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.  

    Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs:  ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea.  In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.  

    Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation:  difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Santarus® and ULTESA™ are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.


    '/>"/>

    SOURCE Santarus, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results
    2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
    3. Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast
    4. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
    5. BD Announces Webcast of Annual Meeting of Shareholders
    6. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
    7. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
    8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
    9. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
    10. Cepheid to Webcast Upcoming Financial Presentation
    11. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
    (Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
    (Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
    (Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
    (Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
    Breaking Medicine News(10 mins):